Severe neonatal encephalopathy (NE), mostly of hypoxic-ischemic (HI) origin, leads to brain injury in term newborns, often causing lifelong motor and cognitive impairment. The primary insult is followed by a self-sustaining destructive cascade 1 that postinsult therapies might limit. No clinical intervention except therapeutic hypothermia (TH) is known to improve the neurologic outcome. [2] [3] [4] A meta-analysis of 7 large randomized controlled cooling trials has shown that poor outcome is reduced from 66% to 50% in cooled infants. [4] [5] [6] [7] Adding the anesthetic gas xenon (Xe) to TH for additional neuroprotection has been investigated in small [8] [9] [10] [11] and large 12 experimental in vivo preclinical outcome studies by us as well as other researchers. Adding 50% Xe to cooling immediately postinsult doubles the neuroprotective effect, 11, 12 as measured by using histologic neuropathology scores, and Xe is effective even after a 2-hour delay. 13 After HI, reperfusion leads to excessive glutamate release, N-methyl-Daspartate receptor overactivation, and calcium influx-mediated apoptotic neuronal death. Xe partially inhibits the N-methyl-D-aspartate receptor, 14 and Xe pretreatment up-regulates the prosurvival proteins Bcl-2 and brainderived neurotrophic factor in rats. 15 Xe is an almost inert elemental gas, 4 times heavier than air and free of adverse physiologic effects or toxicity. [16] [17] [18] It is eliminated unchanged via the lungs within minutes when delivery is stopped and therefore is a potentially reversible intervention. Xe is licensed for adult anesthesia in Europe 19 (LENOXe TM, Air Liquide, Paris, France) and Russia (KseMed, Akela-P Medical Gases Pvt. Ltd, Moscow, Russia; Russian Federation license 64/0125-Л/02 of 19.12.2002) , but the high cost ($30 per liter) and fixed annual production limit its use. The only previous neonatal experience with Xe was from 133 Xe isotope studies. 20 An economical Xe delivery system was developed that recirculates exhaled gases, removes carbon dioxide, and adds oxygen/Xe to replace patient uptake. In preclinical pig studies, 12, 21 0.25 L/h of Xe maintained a steady 50% Xe concentration after initial circuit priming, minimizing costs compared with an open ventilator using up to 180 L/h of Xe. Additional costs included $200 for the single-use ventilation circuit and $80 for the cuffed endotracheal tube.
Adding 50% Xe to TH in both short-term 11 and long-term 13 neonatal brain injury models doubles the neuroprotection compared with TH alone. Moving from a rodent to a larger whole-body HI pig survival model confirmed an additive effect between Xe and TH, resulting in 75% protection in neuropathology. 12 In a newborn pig brain ischemia model, metabolic markers favored the Xe + TH group compared with Xe or TH alone. 22 Xe + TH improved cardiovascular stability and reduced inotropic requirements. 23 There was no increased oxygen requirement, no cuffed tracheal tube complications, and no stridor or extubation delays in either our experimental pig study 12 (n = 120) or this clinical study. There are ongoing concerns regarding neuroapoptosis in the immature brain with inhalation anesthetic agents. 24 Although atypical in mode of action, Xe is an inhalation anesthetic. Recently, we ventilated newborn pigs for 24 hours with 50% Xe, finding no increase in neuroapoptosis over normal controls unlike those ventilated with 2% isoflurane, in which there was a .10-fold increase. 25 A study of 120 newborn pigs provided safety data for all organ systems 26 and supported our use of 50% Xe in this clinical feasibility study in term infants undergoing TH.
METHODS
This was a single-arm, dose-escalation feasibility study adding Xe ventilation to 14 cooled infants with NE. We used the Sarnat clinical severity scoring system 27 (Fig 1D) .
The number of deaths that statistically would require trial suspension, pending review, as calculated for patients 1 through 14 based on a retrospective cooling mortality of 25% is shown in Table 1 . This stopping rule is such that the trial is stopped if the binomial probability for the observed number of deaths is ,0.05 but continued if this value is .0.05. These calculations were made by our study statistician based on this principle and our cooling mortality data over the preceding 6 years.
After initial resuscitation and medical management following usual guidelines for NE and cooling therapy, additional inclusion criteria for Xe were applied: ,18 hours old, weight greater than the second percentile for gestational age, intubated and ventilated, sedated, being cooled, seizures under control, stable cardiovascular parameters, mean arterial blood pressure (MABP) .40 mm Hg, oxygen requirement via mechanical ventilator ,0.35, positive end-expiratory pressure #8 cm H 2 O, arterial/capillary/ venous PCO 2 ,7.0 kPa (ideally arterial), and absence of major congenital abnormalities (in particular, imperforate anus or any bowel obstruction). 4, 6 Thirteen infants were outborn and 1 was inborn. All started "passive" cooling followed by active servo-controlled body cooling by using Criticool (MTRE Advanced Technologies Ltd, Rehovot, Israel) (n = 12) or Tecotherm Neo (Inspiration Healthcare Ltd, Leicester, UK) (n = 2) machines. Umbilical arterial/ venous catheters were inserted for arterial pressure, blood gas measurements, fluid infusions of dextrose with electrolytes (n = 12), or total parenteral nutrition (n = 2), sedatives, anticonvulsants, inotropes, and antibiotics. Routine sedation for ventilated infants was 20 mg/kg per hour of morphine. Hourly neonatal facial coding scoring for pain evaluation was performed, and the dose adjusted accordingly. 29 Clinical or subclinical seizures recognized on an amplitude-integrated EEG (aEEG) and an EEG (Olympic CFM 6000, Natus Medical Incorporated, San Carlos, California) lasting .3 minutes were treated with anticonvulsants. The first infant who received Xe during cooling was given 25% Xe for 3 hours; the following infants received 50% Xe for 3, 6, 12, or 18 hours (Table 2) . Because no human neonate had previously received Xe, we gradually increased the treatment duration to our target of 18 hours, which is the amount shown to be neuroprotective in the preclinical study. 12 Figure 1 shows the monitoring and breathing system assembly. 21 (see Supplemental Video) The closed ventilator circuit was partially flushed with fresh gas every 2 hours as a precaution. Cardiovascular, respiratory, and aEEG/EEG responses, including seizures, were monitored closely during Xe initiation (0% to 50%) and weaning (50% to 0%). Xe onset and offset were initially performed slowly over 45 minutes as a precautionary measure, then reduced gradually to 7 minutes. On stopping Xe, conventional ventilation was resumed, the endotracheal tube cuff deflated, and the tube left in situ. Protocols for hypotension, hypoxemia, infection risk, abnormal carbon dioxide levels, seizures, reintubation, and extubation followed standard clinical practice.
RESULTS
The cohort recruited was typical, with 4 infants assessed as grade 2 HIE and 9 as grade 3 HIE on day 1 (Table 3) . 27 Cooling commenced pretransfer, and the target temperature was reached between 2.4 and 9.7 hours of age ( 
a Based on 25% mortality in the cooled cohort, it is not unlikely that the first 2 consecutive infants might die (P = .06). If the third infant also dies, the probability that this is a random event is very small (P = .016); thus, the study should stop and review after 3 deaths. Xe did not reduce MABP below critical values.
A severely depressed aEEG with either burst suppression (BS), low amplitude, or flat tracing (Table 3) , both before cooling and before Xe, occurred in 10 infants; these infants were also classified as grade 3 HIE on day 1. Eight infants had documented clinical or EEG seizures before Xe (6 had received phenobarbital); however, only 1 of 14 had a seizure during Xe administration. Figure 4 illustrates the depressant effect of Xe on aEEG at Xe onset in 2 infants. In Fig 4A, Sedation and inotropic support are summarized in Table 3 . The Neonatal Facial Coding System score for pain evaluation (range: 0-2, where 0 = no pain) was 0 throughout except for 1 child with a value of 2 after rapid Xe cessation. The mean morphine dose did not change during the 3-to 6-hour period before, during, or after Xe. Ten infants required inotropic support; in 4 infants, this support was started before cooling. There was no association between starting and stopping of inotropes as a result of starting or stopping Xe. Cooling normally reduces heart rate, and the addition of Xe caused a further reduction; however, MABP was maintained (Figs 5B, 5C, and 5D).
All infants received intravenous antibiotics after birth for $2 days because infection could not be initially excluded. No infant had a positive blood culture result. One mother had an elevated C-reactive protein (CRP) level .100 mg/L and a positive blood culture result. In addition, 6 mothers had cultures taken (the results of which were all later confirmed as negative) and were treated with intravenous antibiotics during delivery. Data were collected from 3 cooled patients with similar baseline variables (n = 42) matched to each Xe-treated patient. All had routine CRP measured 1 to 2 times daily. We compared the time course and peak CRP value during the first 3 days of life between the Xe group and the 42 matched control subjects. There was The aEEG was analyzed by using pattern recognition 28 
DISCUSSION
This feasibility study describes the use of Xe as a second neuroprotectant in human term infants undergoing hypothermia. Xe is an expensive and scarce anesthetic gas; either of these factors may limit its use as a neuroprotectant. We addressed this limitation by developing a closed-circuit Xe delivery
FIGURE 2
Absolute values (mean 6 SD) of heart rate, MABP, FIO 2 , TcSO 2 , ETCO 2 , peak inspiratory pressure (PIP), and positive end expiratory pressure (PEEP) during 3 periods: 4 to 6 hours before Xe, the entire Xe period (3-18 hours), and a 0-to 6-hour period after Xe administration. Mean Xe concentration was 50 6 2%.
FIGURE 3
MABP 1 hour before Xe administration, at the start and cessation of Xe, and 1 hour after Xe administration. Median MABP on starting Xe was 50 mm Hg and did not differ on cessation of Xe (46 mm Hg).
system 21 in which the net use of Xe gas to maintain a steady 50% concentration was only 0.29 L/h. As a precaution, we followed anesthesia clinical practice by periodically flushing the circuit with fresh gas. The overall Xe requirement, incorporating these flushes and an initial bolus to prime the circuit, was 0. Permission to study humans was given in view of the additive neuroprotective effect of Xe plus TH in both rodents 9, 11, 13 and pigs, 12 near-inert chemistry, acceptable cost if delivered efficiently, and the reversibility of the treatment. Another advantage is that Xe is known to be relatively free of hemodynamic adverse effects. 22 The optimal duration of Xe plus TH treatment is unknown. We chose a maximum of 18 hours of 50% Xe because this combination doubled histologic neuroprotection compared with hypothermia alone in a global newborn piglet model. 12 In rodents, as little as 1 hour of 50% Xe during TH increased neuroprotection. 13 There are several important safety issues regarding inhalation anesthetics and the immature brain. Isoflurane applied for a few hours can induce neuroapoptosis in rodents. 30 Recently, we were reassured that 24 hours of 50% Xe did not increase neuroapoptosis in newborn healthy pigs; in contrast, 2% isoflurane increased apoptosis .10-fold. 25 The neuroapoptotic effect is therefore not shared by all inhalation anesthetic agents, and Xe is more likely than others to be safe for the immature brain.
The sedative effect of Xe per se cannot be assessed reliably in infants with varying degrees of cerebral depression. Some were comatose and unresponsive; others needed increased morphine sedation during hypothermia. However, it was apparent clinically and on EEG that 50% Xe increased sedation (Fig 4) . Although Xe is 4 times denser than oxygen, at 50%, it only minimally changes overall viscosity. 32 High Xe concentrations in pigs produce only a modest airway pressure increase. 33, 34 In dogs, high concentrations only modestly increase airway resistance, even after drug-induced bronchoconstriction. 35 In our study, ETCO 2 was unchanged in the presence of Xe. Cuffed tubes were used to prevent Xe loss and are necessary for a closed breathing system. We acknowledge previous concerns regarding the cuffed endotracheal tubes but observed no stridor or extubation problems in 120 pigs 12 or these 14 study infants. In an anesthesia study in 2246 children, 326 of whom were ,8 months old, extubation stridor occurred in 4.4% of those with cuffed tubes and 4.7% of those without. 36 Xe diffusion into tube cuffs has been investigated by others and is likely to be slow. 37 As a precaution, we monitored the cuff pressure hourly. It has been suggested that Xe interacts with the immune system by preserving neutrophil and monocyte antibacterial capacity and modulation of inflammatory cytokines such as tumor necrosis factor-a and interleukin-6 in monocytes. 38, 39 In the present study, Xe had no effect on the commonly monitored inflammatory marker CRP. We compared degree and timing of the individual CRP responses withdatafrommatchedchildren undergoing cooling only. Modulation of inflammatory responses or immune tissue damage by Xe may in the future reveal additional protective responses with respect to other organ systems, for which there is already some evidence from animal studies. [40] [41] [42] 
CONCLUSIONS
Breathing 50% Xe for up to 18 hours in conjunction with 72-hour cooling in term and near-term infants with NE at birth by using a closed Xe breathing system and cuffed endotracheal tube was feasible with no adverse effects. No significant cardiovascular or respiratory changes during or after Xe administration were seen in these study patients. Cuffed endotracheal tubes (with cuff pressure monitoring) did not adversely affect extubation. Xe did not influence the peak CRP or time course for the first 3 days after birth. Xe depressed EEG in those who were not comatose and also depressed seizures because some infants started to experience seizures when Xe was discontinued. Attention to slow weaning and the level of sedation are required when Xe is stopped. Outcome at 18 months, reported for safety purposes, showed no delay or mild delay in 50% of these patients, which is similar to and no worse than expected from cooling alone. This study confirmed that it is feasible and safe to do a Phase II randomized outcome study combining TH with 50% Xe, and that study is now underway. 
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